Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: Provided is a method for constructing an atopic dermatitis skin organoid from human pluripotent stem cells. It was observed that ALI-skin organoids of the presently claimed subject matter formed skin cells, appendages, neural cells, adipocytes, and the like in similar structures to those in the real skin and exhibited greatly improved follicle growth, compared to skin organoids constructed by existing culture methods. In addition, as a result of treatment with Staphylococcus aureus to construct an atopic dermatitis model, a good simulation was made of the characteristics of atopic dermatitis, such as damaged skin barriers, increased epithelium-derived cytokines and downregulated epidermal stem cell expression, causing Staphylococcus aureus colonies, and the like. Thus, the skin organoid of the presently claimed subject matter is expected to find advantageous applications as a real skin model and an atopic dermatitis model.

Abstract: The present invention relates to the field of detection of dimethyltryptamine. In order to solve the problems in the prior art that liquid chromatography-tandem mass spectrometry for detection of dimethyltryptamine has high requirements for instruments and operators and is difficult to popularize and low in detection speed, the present invention discloses a dimethyltryptamine hapten, an artificial antigen and preparation methods and application thereof. The dimethyltryptamine hapten is obtained by a reaction of N,N-dimethyl-5-hydroxytryptamine as a precursor and glutaric anhydride. The artificial dimethyltryptamine antigen obtained from the dimethyltryptamine hapten can be used for preparing a dimethyltryptamine monoclonal antibody and a dimethyltryptamine colloidal gold-fluorescence test paper.

Abstract: Disclosed is an automatic cleaning and separating device for removing uncombined components in reactants in a reaction container. The automatic cleaning and separating device includes: a liquid injection and uniform mixing mechanism, a removal assembly and a liquid suction mechanism; wherein a liquid injection driver is mounted on the liquid injection and uniform mixing mechanism, a liquid suction driver is mounted on the liquid suction mechanism, the liquid injection driver drives the liquid injection and uniform mixing mechanism to move up and down so as to complete liquid injection, the liquid suction driver drives the liquid suction mechanism to move up and down to complete liquid suction, and the removal assembly removes the reaction container from the liquid injection and uniform mixing mechanism under the relative motion of the liquid suction mechanism and the liquid injection and uniform mixing mechanism.

Abstract: A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R1, R12, and R13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

Abstract: The present disclosure relates to Alkynylphenylbenzamide compounds and the applications thereof. The said Alkynylphenylbenzamide compounds have the structure shown in Formula (I). The compounds can be used as protein kinase inhibitors, which can effectively inhibit the activity of TRK protein kinase and the proliferation, migration and invasion of various tumor cells. At the same time, it has the characteristics of good pharmacokinetics and low toxicity.

Abstract: The present invention relates to a whey-derived polar lipid-concentrated fraction composition, being a single-phase composition derived from a whey protein concentrate, wherein the composition is derived from a fraction obtained by treating the whey protein concentrate with a water-containing spirit, a total lipid content is 90 percent by weight (wt %) or more with respect to a dry weight of the composition, and a phospholipid content is 35 wt % or more with respect to the total lipid weight. According to the present invention, a whey-derived polar lipid-concentrated fraction composition in a stable form that maximizes emulsification and physiological functionality may be prepared.

Abstract: A purification method of fungal cell wall composition includes following steps: (1) taking a residue of a fungus fruiting body underwent extraction process for obtaining extract thereof, wherein the extract contains terpenoids, sterols, polysaccharides, or a combination thereof, and the residue contains the cell wall of the fruiting body; (2) placing the residue into an aqueous percarbonate solution to form a mixture liquid, which is reacted at a first temperature for decolorizing the residue, wherein the concentration of the aqueous percarbonate solution ranges from 5 to 20% (w/v), and the first temperature ranges from 15 to 40° C.; (3) after the decolorization process, raising the temperature of the mixture liquid to a second temperature for the mixture liquid to react, so as to digest and decompose the residue, wherein the second temperature ranges from 80 to 100° C.; and (4) filtering the treated mixture liquid to obtain a purified product.

Abstract: The present disclosure provides a preparation method of tofacitinib citrate, which comprises the following steps: passing an intermediate TOF-2 into hydrogen at a normal pressure in the presence of a catalyst to obtain an intermediate TOF-3; in the presence of a solvent and a base, under a reduced pressure of ?490 mmHg to ?760 mmHg, and at a temperature of 10° C. to 25° C., reacting TOF-3 with ethyl cyanoacetate to generate an intermediate TOF-4; heating and dissolving TOF-4 and citric acid in a solvent, and performing separation by cooling to obtain tofacitinib citrate. The present disclosure obtains tofacitinib citrate with high yield, high purity and low impurities by changing a gas flow rate and a reaction temperature and pressure of a hydrogenation reaction. Therefore, the preparation method is suitable for industrial production.

Abstract: A method for preparing a Plectranthus amboinicus (PA) extract, the method comprising extracting an above-ground part of Plectranthus amboinicus with an extracting solution that comprises a solvent having a suitable polarity index, filtrating and concentration the extract thus produced, and subject the concentrated extract to a chromatographic separation process using a hydrophobic interaction chromatography resin to produce the PA extract.

Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: A method for laser distance measuring includes: emitting an incident ray ? having an incident angle ? to a reflective surface of a laser reflecting mirror (31), the incident ray ? being reflected by the laser reflecting mirror (31) to generate a first reflected ray ?, and the first reflected ray ? irradiating an object to be measured (1000); capturing a second reflected ray ? and generating a laser image on a laser imaging plane (3221), the second reflected ray ? being generated by the reflective surface of the laser reflecting mirror (31) reflecting a return ray ? generated after the first reflected ray ? irradiates a surface of the object to be measured; and determining, based on the laser image, a measurement distance A according to a geometrical trigonometry.

Abstract: A breathing airflow detecting device for a nebulizing device is disclosed. The breathing airflow detecting device includes a case, wherein a light switching module and a light blocking element are arranged in the case. The light blocking element is arranged between optical routes of a light emitting element and a light receiving element. When airflow from an inlet blows and swings the light blocking element, the light blocking element blocks light or passes light to the light receiving element. When the light receiving element detects the variation of light, the light receiving element emits a signal from the output port of the light switching module to drive or stop driving a nebulizing device. As a result, when a patient breathes, the nebulizing device is driven such that the volume of the nebulized medicine is accurately inhaled into the patient's lungs.

Abstract: The present disclosure disclose a microscopic device and a focusing method of the microscopic device, the microscopic device includes an object stage configured to carry a transparent carrier and drive the transparent carrier to translate along at least one direction, the transparent carrier includes at least two object positions; a microscopic objective located on a side of the object stage; a rangefinder located on a same side of the object stage as a microscopic objective and at a same height relative to the object stage, and the rangefinder is configured to measure a distance between a surface of each of the at least two object positions and the microscopic objective; a focusing module configured to adjust a position of the microscopic objective along a first direction based on the distance measured by the rangefinder, wherein the first direction is perpendicular to a carrying surface of the object stage.

Abstract: A method of treating central nervous system (CNS) diseases in a subject is provided. The method comprises administering to the subject a therapeutically effective amount of Antcin H and/or its derivatives. The novel use of Antcin H and/or its derivatives are also provided.

Abstract: The present disclosure provides an in vitro life culture system, comprising: a culture module used to cultivate a culture, the culture module including at least a culture chamber for holding a culture fluid; a culture fluid provision module used to provide the culture fluid to the culture module; and a fluid output module used to discharge the culture fluid from the culture chamber.

Abstract: The present invention relates to a composition for preventing sleep disorders or insomnia, containing an enzyme-treated Ashwagandha extract as an active ingredient, and specifically, since it was confirmed that in an animal model and a sleep disorder animal model, which were administered an enzyme-treated Ashwagandha extract, sleep latency and awake time during sleep were decreased, sleep time, non-rapid eye movement (NREM) sleep time and ?-waves were increased, and as a result, sleep activity was improved, the enzyme-treated Ashwagandha extract can be used as an active ingredient of a composition for preventing or treating sleep disorders or insomnia.

Abstract: A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method and use thereof are provided. The immune DNA vaccine ZD-nCor19 provided herein uses RBD protein, residues 301-538 in the S2 subunit and residues 138-369 in the N protein of the novel coronavirus as target antigens, and has specific immune synergism molecules introduced at suitable positions, and thus can simultaneously efficiently induce humoral immunity and cellular immunity, and can avoid safety problems associated with ADE that may be generated by the full-length S protein and the full-length N protein, thereby achieving dual effects of prevention and treatment. The vaccine can be used as a safe, efficient and stable vaccine variety against novel coronavirus infection.